Pomdoctor Limited Reports 16.7% Revenue Growth to RMB399.9M, Net Loss Widens
POM•Pomdoctor Limited's fiscal 2025 net revenues rose 16.7% to RMB399.9 million, driven by a 69.3% surge in Internet hospital sales to RMB150.7 million, while gross profit climbed 9.6% to RMB52.3 million. Net loss widened to RMB130.9 million mainly due to one-time IPO expenses despite a 328.5% R&D investment increase.
1. Fiscal 2025 Financial Highlights
Pomdoctor recorded net revenues of RMB399.9 million in fiscal 2025, up 16.7% from RMB342.6 million a year earlier. Growth was led by Internet hospital revenue of RMB150.7 million, a 69.3% increase, reflecting expanded online pharmacy sales.
2. Cost of Revenue and Margins
Cost of revenue rose 17.9% to RMB347.6 million, driven by higher online pharmacy costs. Gross margin slipped to 13.1% from 13.9%, as lower-margin products grew faster, with Internet hospital margin falling to 32.7%.
3. Strategic Investments and Net Loss
R&D expenses jumped 328.5% to support AI-driven services and platform upgrades. Despite operational gains, net loss expanded to RMB130.9 million due to significant non-recurring IPO-related fees.
